As CAR-T therapies mature and look to scale out, a current barrier exists between the number of patients in need of these therapies and highly skilled operator availability. Automation in biopharmaceuticals and cell therapy manufacturing addresses this gap, along with helping reduce the risk of contamination and ensures operator safety.